Robert Alan Kloner

Robert Alan Kloner, MD, PhD is a Professor of Medicine (Clinical Scholar) at the Keck School of Medicine of the University of Southern California. His extensive research focuses on cardiovascular disease, particularly myocardial infarction, cardioprotection, and the relationship between erectile dysfunction and cardiovascular risk. Dr. Kloner has made significant contributions to understanding the no-reflow phenomenon, ischemia/reperfusion injury, and the cardiovascular effects of various substances.

His research interests span several critical areas in cardiology including mechanisms of myocardial infarction, cardioprotective strategies during reperfusion, the no-reflow phenomenon, and the cardiovascular implications of erectile dysfunction. Dr. Kloner has extensively studied the effects of substances including marijuana, cocaine, and electronic cigarettes on cardiovascular function. He has been instrumental in developing consensus guidelines for the management of erectile dysfunction in patients with cardiovascular disease through the Princeton Consensus Conferences.

Dr. Kloner's recent work demonstrates a continued focus on contemporary cardiovascular challenges, including the cardiovascular effects of marijuana legalization, electronic cigarette impacts on cardiac function, and the management of cardiovascular disease during the COVID-19 pandemic. His publication record shows consistent productivity with numerous high-impact articles appearing in leading cardiology journals.

Among his many honors, Dr. Kloner has been listed in Guide to America's Top Cardiologists, received the Physician Leadership Award from Good Samaritan Hospital, and was identified as one of the world's most highly cited authors by the Institute for Scientific Information. He was also elected as a Member of the American Society for Clinical Investigation and received the Established Investigatorship Award from the American Heart Association.

Dr. Kloner has served on the NIH Cardiovascular Study Section and has been involved in numerous consensus panels addressing critical intersections between sexual health and cardiovascular medicine. His work bridges basic science with clinical applications, particularly in understanding how pharmacological interventions can protect the heart during ischemic events.